DOCSLIB.ORG

Landispiwowar.Kristin.Genetics of Select Lymphoproliferative

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Landispiwowar.Kristin.Genetics of Select Lymphoproliferative 3/21/16 Objecves Gene+cs of Select • Define tumor suppressor gene and oncogene Lymphoproliferave Neoplasms: • Correlate genotypes Pathophysiology, Prognos+caon, and Therapy with prognosis in lymphoproliferave neoplasms Kris+n Landis-Piwowar PhD, MLS(ASCP)CM • Recognize the targets of lymphoproliferave Clinical Laboratory Hematology, 3/E, McKenzie • Williams neoplasm therapies 2 Leukemia Lymphoma WHO 2008: Mature B-Cell Neoplasms • Chronic lymphocy+c leukemia/small lymphocy+c • Mantle cell lymphoma lymphoma • Diffuse large B-cell lymphoma (DLBCL), NOS • Primarily BM and • Primarily lymph • B-cell prolymphocyc leukemia • T-cell/his+ocyte rich large B-cell lymphoma • Primary DLBCL of the CNS • Splenic marginal zone lymphoma • Primary cutaneous DLBCL, leg type blood involvement node / solid ssue • Hairy cell leukemia • EBV-posi+ve DLBCL of the elderly • Splenic lymphoma/leukemia, unclassifiable • DLBCL associated with chronic inflammaon • Splenic diffuse red pulp small B-cell lymphoma • Lymphomatoid granulomatosis • Hairy cell leukemia variant involvement • Primary medias+nal (thymic) large B-cell lymphoma • Myeloid or • Lymphoplasmacy+c lymphoma • Intravascular large B-cell lymphoma • Waldenström macroglobulinemia • ALK-posi+ve large B-cell lymphoma lymphoid origin • Lymphoid origin • Heavy chain diseases • α Heavy chain disease • Plasmablas+c lymphoma • γ Heavy chain disease • Large B-cell lymphoma arising in HHV8-associated • May secondarily • May secondarily • μ Heavy chain disease mul+centric Castleman disease • Plasma cell myeloma • Primary effusion lymphoma • Solitary plasmacytoma of bone • Burkih lymphoma involve lymph involve BM & • Extraosseous plasmacytoma • B-cell lymphoma, unclassifiable, with features intermediate • Extranodal marginal zone lymphoma of mucosa-associated between diffuse large B-cell lymphoma and Burkih nodes and solid blood; “leukemic lymphoid +ssue (MALT lymphoma) lymphoma • Nodal marginal zone lymphoma • B-cell lymphoma, unclassifiable, with features intermediate ssues phase” • Pediatric nodal marginal zone lymphoma between diffuse large B-cell lymphoma and classical • Follicular lymphoma Hodgkin lymphoma • Pediatric follicular lymphoma • Primary cutaneous follicle centre lymphoma Adapted from: Clinical Laboratory Hematology, 3/E, McKenzie • Williams 4 3 WHO 2008: Mature T-Cell Neoplasms WHO 2008: More Neoplasms • T-cell prolymphocyc leukemia • • Hodgkin lymphoma • B lymphoblas+c leukemia/lymphoma Sézary syndrome • Nodular lymphocyte predominant Hodgkin lymphoma • B lymphoblas+c leukemia/lymphoma, NOS • T-cell large granular lymphocy+c • Primary cutaneous CD30+ T-cell • Classical Hodgkin lymphoma • B lymphoblas+c leukemia/lymphoma with recurrent leukemia • Nodular sclerosis classical Hodgkin lymphoma gene+c abnormali+es lymphoproliferave disorders • Lymphocyte-rich classical Hodgkin lymphoma • B lymphoblas+c leukemia/lymphoma with t(9;22) (q34;q11.2);BCR-ABL 1 • • Chronic lymphoproliferave disorder of • Lymphomatoid papulosis Mixed cellularity classical Hodgkin lymphoma • B lymphoblas+c leukemia/lymphoma with t(v; NK cells • Lymphocyte-depleted classical Hodgkin lymphoma 11q23);MLL rearranged • Primary cutaneous anaplas+c large cell • B lymphoblas+c leukemia/lymphoma with t(12;21) • Aggressive NK-cell leukemia lymphoma (p13;q22) TEL-AML1 (ETV6-RUNX1) • His+ocy+c and dendri+c cell neoplasms • B lymphoblas+c leukemia/lymphoma with • Systemic EBV-posi+ve T-cell • Primary cutaneous γδ T-cell lymphoma • His+ocy+c sarcoma hyperdiploidy lymphoproliferave disease of • Langerhans cell his+ocytosis • B lymphoblas+c leukemia/lymphoma with hypodiploidy • Langerhans cell sarcoma • B lymphoblas+c leukemia/lymphoma with t(5;14) • Primary cutaneous CD8+ aggressive (q31;q32) IL3-IGH childhood • Interdigitang dendri+c cell sarcoma epidermotropic cytotoxic T-cell • B lymphoblas+c leukemia/lymphoma with t(1;19) • Hydroa vacciniforme-like lymphoma • Follicular dendri+c cell sarcoma (q23;p13.3);TCF3-PBX1 lymphoma • Fibroblas+c re+cular cell tumor • Adult T-cell leukemia/lymphoma • Intermediate dendri+c cell tumor • T lymphoblas+c leukemia/lymphoma • Primary cutaneous CD4+ small/medium • • Extranodal NK/T-cell lymphoma, nasal Disseminated juvenile xanthogranuloma T-cell lymphoma • Acute leukemias of ambiguous lineage type • Poshransplantaon lymphoproliferave disorders • Peripheral T-cell lymphoma, NOS (PTLDs) • Acute undifferen+ated leukemia • Enteropathy-associated T-cell • Mixed phenotype acute leukemia with t(9;22)(q34;q11.2); • Early lesions BCR-ABL1 lymphoma • Angioimmunoblas+c T-cell lymphoma • Plasmacy+c hyperplasia • Mixed phenotype acute leukemia with t(v;11q23); MLL • Hepatosplenic T-cell lymphoma • Infec+ous mononucleosis–like PTLD rearranged • Anaplas+c large cell lymphoma, ALK- • Polymorphic PTLD • Mixed phenotype acute leukemia, B-myeloid, NOS • • Subcutaneous panniculi+s-like T-cell posive Monomorphic PTLD (B- and T/NK-cell types) • Mixed phenotype acute leukemia, T-myeloid, NOS • lymphoma Classical Hodgkin lymphoma type PTLD • Provisional en+ty: natural killer (NK) cell lymphoblas+c • Anaplas+c large cell lymphoma, ALK- leukemia/lymphoma • Mycosis fungoides negave 5 6 1 3/21/16 Posi+on effect leads to new Pathophysiology Gene A promoter Gene B coding region expression rate • Chromosome Alteraons • Unbalanced: Change in total gene+c informaon Gene B coding region (addi+ons / dele+ons) Gene A coding region • Balanced: Gene+c informaon Del 17p (8%) rearranged Expression of trisomy 12 fusion genes with (12–16%) • DNA alteraons new funcon Del 11q • Single nucleode (18%) • Inser+ons Del 13q Breakpoint effect • Deleons (55%) CLL deletes coding • Duplicaons region and leads 7 to loss of func+on 8 Chromosomal Endogenous translocaons Growth Growth factor Exogenous factors receptors • Free radicals Gene • DNA replicaon errors • Ionizing radiaon amplificaon Signal Transcrip+on • V(D)J recombinaon • Chemicals transducers factors • Class switching Proto- • Drugs • Somac hypermutaon Retroviral oncogenes transduc+on Double Strand Breaks Inser+onal Gain of mutagenesis Funcon M G Point Oncogenes 1 mutaons Promote Cell Death G2 S DNA Repair proliferaon DNA Incorrect Neoplas+c cells in damaging peripheral blood event Genomic Instability Carcinogenesis Carcinogenesis Normal Cells in peripheral blood Bone marrow HSC pool 10 Adapted from: Clinical Laboratory Hematology, 3/E, McKenzie • Williams Growth Growth factor Oncogenes Promote factors receptors Lymphoproliferaon Signal Transcrip+on transducers factors Signal Transcrip+on Dimerizaon / Receptors Transducers Factors Transmembrane Ac+vaon Receptors (RTKs) BRAF NOTCH STAT3 BCL2 1. Receptor-growth factor BCR-ABL1 ETV6-RUNX1 BCR binding MYD88 BIRC3 TCF3-PBX1 2. Signal transduc+on JAK3 CD79A/B 3. Gene expression NOTCH MYC-IGH2 DNA RNA Protein 12 2 3/21/16 M G1 Growth Growth factor factors receptors Both alleles Cell Death G2 S DNA Repair must be affected Signal Transcrip+on Two-hit Incorrect transducers factors Inherited / hypothesis Sporadic Dimerizaon / Loss of Funcon Transmembrane Ac+vaon Tumor Receptors (RTKs) Suppressor Genes Inhibit proliferaon 1. Receptor-growth factor binding Carcinogenesis 2. Signal transduc+on 3. Gene expression DNA RNA Protein 13 Tumor Suppressors Inhibit Lymphoproliferaon Epigenecs • “On top of gene+cs” Signal Transcrip+on Epigenec • Informaon carried by the Transducers Factors Regulators genome that is not encoded Brooker by DNA ATM SF3B1 • DNA provides the gene+c plan P53 • Other factors affect how that plan will be expressed SF3B1 miR15/16 • DNA methylaon Brooker • Histone modificaons miRNA • Non-coding RNA (miRNA) 15 16 RNA interference Cancer Evolves by Natural Selec+on Depletes mRNA via (miRNA) sequence-specific pairing • Cancer is mul+ple different (sub-clonal) cancers occupying the same or dis+nct +ssue environments microRNA: Non-protein coding RNA Establishes and • Clonal expansion results due to compe++ve maintains ssue- advantage (proliferave or survival) over other (18 – 24 nucleo<des) binds mRNA specific expression sub-clones profile • Number of mutaons can vary from few (10–20) to hundreds of thousands • Most are ‘passengers’ (no effect on growth advantage) mRNA Translaonal • Others are func+onally relevant ‘drivers’ (confers degradaon inhibion selec+ve growth advantage) 18 17 3 3/21/16 Diffuse Walden- Chronic Hairy cell T-cell large Plasma cell T-cell acute Clonal Evolu+on is an Interplay of large B-cell ström lympho- leukemia granular myeloma lympho- lymphoma macro- cyc lympho- blasc Gene+c Changes: (DLBCL), globulin- leukemia cyc leukemia NOS emia leukemia CD79A 20% - - - - - - Selecvely • Survival/an+-apoptosis mutaon advantageous ‘driver’ CD79B 20% - - - - - - • Oncogenes mutaon lesions MYD88 30-75% 68-100% 2-10% - - - - mutaon Selec+vely neutral • Mono-alleleic loss NOTCH1 8% - 5-20% - - - >60% mutaon ‘passenger’ lesions • Tumor suppressors NOTCH2 8% - - - - - - mutaon BRAF 4% - - 99-100% - ??? - • Increase the rate of other gene+c changes mutaon ‘Mutator’ lesions - - - - • DNA repair genes SF3B1 - - 5-23% STAT3 3-5% - - - 28-40% 50% - P53 - - 10% - - 10% - Changes to the micro-environment miR 15a/ ??? - 55-66% - - Up to 50% - 19 16-1 20 MYD88 MYD88 • Toll-like receptors (TLR) are central to B-cell • MYD88 L265P missense clonal ‘driver’ receptor-independent an+gen response mutaon • Sense pathogen-associated molecular paerns • Iden+fied in 2011 in DLBCL (2012; WM) (bacteria, viruses, and fungi) • Gain of func+on to drive NF-kB • Ini+ates intracellular signaling (MYD88) Toll-interleukin-1 receptor domain DD TIR NF-kB IRAK interac+on L265P Promotes
Load more

Recommended publications
  • Lymphomatoid Papulosis and Recurrent Transitional Cell Carcinoma
    Volume 20 Number 4 April 2014 Letter Lymphomatoid papulosis and recurrent transitional cell carcinoma of the bladder: a paraneoplastic association WMS Leong1, CWD Aw1, KB Tan2 Dermatology Online Journal 20 (4): 17 1Division of Dermatology, National University Hospital, Singapore 2Department of Pathology, National University Hospital, Singapore Correspondence: Wai Mun Sean Leong, M.B.B.S. University Medicine Cluster National University Hospital 5 Lower Kent Ridge Road Singapore 119074 Phone: 67795555 Email: [email protected] Abstract Lymphomatoid papulosis is a rare, papulonodular skin eruption with histologic features of a CD30+ T cell lymphoma. We present a 79-year-old man with lymphomatoid papulosis and transitional cell carcinoma of the bladder. Introduction Lymphomatoid papulosis (LyP) is a rare, recurrent, self-healing papulonodular skin eruption with histologic features of a CD30+ malignant T cell lymphoma [1]. It belongs to a group of cutaneous CD30+ lymphoproliferative disorders, which includes cutaneous T cell lymphoma [2]. Patients with LyP are at risk of developing a second cutaneous or nodal lymphoma [3,4]. However, an association with transitional cell carcinoma (TCC) of the bladder has not been reported in the literature. This case illustrates a possible association between these two conditions. Case synopsis A 79-year-old man complained of a slightly itchy rash on the arms, neck, and shoulders for one year. Betamethasone- gentamicin cream previously afforded partial improvement. Approximately 9 months prior to presentation at the dermatology clinic, he was diagnosed to have TCC of the bladder (T1G3) and had undergone a trans-urethral resection of bladder cancer (TURBT) in December 2006 and January 2007.
    [Show full text]
  • Comorbidities in Mycosis Fungoides and Racial Differences In
    medicines Article Comorbidities in Mycosis Fungoides and Racial Differences in Co-Existent Lymphomatoid Papulosis: A Cross-Sectional Study of 580 Patients in an Urban Tertiary Care Center Subuhi Kaul 1,*, Micah Belzberg 2, John-Douglas Matthew Hughes 3, Varun Mahadevan 2 , Raveena Khanna 2, Pegah R. Bakhshi 2, Michael S. Hong 2, Kyle A. Williams 2, 2 2, 2, Annie L. Grossberg , Shawn G. Kwatra y and Ronald J. Sweren y 1 Department of Medicine, John H. Stroger Hospital of Cook County, Chicago, IL 60612, USA 2 Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA; [email protected] (M.B.); [email protected] (V.M.); [email protected] (R.K.); [email protected] (P.R.B.); [email protected] (M.S.H.); [email protected] (K.A.W.); [email protected] (A.L.G.); [email protected] (S.G.K.); [email protected] (R.J.S.) 3 Section of Dermatology, University of Calgary, Alberta, AB T2N 1N4, Canada; [email protected] * Correspondence: [email protected]; Tel.: +1-312-864-7000 Considered co-senior authors. y Received: 26 October 2019; Accepted: 24 December 2019; Published: 26 December 2019 Abstract: Background: Mycosis fungoides (MF) is a cutaneous T-cell lymphoma. Previous reports have suggested MF is associated with inflammatory conditions such as psoriasis, increased cardiovascular risk factors as well as secondary neoplasms. Methods: A cross-sectional study of MF patients seen from 2013 to 2019 was performed. Comorbidities were selected based on the 2015 Medicare report highlighting the most common chronic medical illnesses in the United States.
    [Show full text]
  • Primary Cutaneous Anaplastic Large Cell Lymphoma / Lymphomatoid
    Primary Cutaneous CD30-Positive T-cell Lymphoproliferative Disorders Definition A spectrum of related conditions originating from transformed or activated CD30-positive T-lymphocytes May coexist in individual patients Clonally related Overlapping clinical and/or histological features Clinical, histologic, and phenotypic characteristics required for diagnosis Types 1. Primary cutaneous anaplastic large cell lymphoma (C-ALCL) 2. Lymphomatoid papulosis 3. Borderline lesions C-ALCL: Definition T-cell lymphoma, presenting in the skin and consisting of anaplastic lymphoid cells, the majority of which are CD30- positive Distinction from: (a) systemic ALCL with cutaneous involvement, and (b) secondary high-grade lymphomas with CD30 expression In nearly all patients disease is limited to the skin at the time of diagnosis Assessed by meticulous staging Patients should not have other subtypes of lymphoma C-ALCL: Synonyms Lukes-Collins: Not listed (T-immunoblastic) Kiel: Anaplastic large cell Working Formulation: Various categories (diffuse large cell; immunoblastic) REAL: Primary cutaneous anaplastic large cell (CD30+) lymphoma Related terms: Regressing atypical histiocytosis; Ki-1 lymphoma C-ALCL: Epidemiology 25% of the T-cell lymphomas arising primarily in the skin. Predominantly in adults/elderly and rare in children. The male to female ratio is 1.5-2.0:1. C-ALCL: Sites of Involvement The disease is nearly always limited to the skin at the time of diagnosis Extracutaneous dissemination may occur Mainly regional lymph nodes Involvement of other organs is rare C-ALCL: Clinical Features Most present solitary or localized skin lesions which may be tumors, nodules or (more rarely) papules Multicentric cutaneous disease occurs in 20% Lesions may show partial or complete spontaneous regression (similar to lymphomatoid papulosis) Cutaneous relapses are frequent Extracutaneous dissemination occurs in approximately 10% of the patients.
    [Show full text]
  • 18F-FDG Avidity in Lymphoma Readdressed: a Study of 766 Patients
    Journal of Nuclear Medicine, published on December 15, 2009 as doi:10.2967/jnumed.109.067892 18F-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients Michal Weiler-Sagie1, Olga Bushelev2, Ron Epelbaum2,3, Eldad J. Dann2,4,5, Nissim Haim2,3, Irit Avivi2,5, Ayelet Ben-Barak6, Yehudit Ben-Arie2,7, Rachel Bar-Shalom1,2, and Ora Israel1,2 1Department of Nuclear Medicine, Rambam Health Care Campus, Haifa, Israel; 2Ruth and Bruce Rappaport Faculty of Medicine, Technion–Israel Institute of Technology, Haifa, Israel; 3Department of Oncology, Rambam Health Care Campus, Haifa, Israel; 4Blood Bank and Apheresis Unit, Rambam Health Care Campus, Haifa, Israel; 5Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel; 6Department of Pediatric Hematology-Oncology, Meyer Children’s Hospital, Rambam Health Care Campus, Haifa, Israel; and 7Department of Pathology, Rambam Health Care Campus, Haifa, Israel PET/CT with 18F-FDG is an important noninvasive diagnostic tool for management of patients with lymphoma, and its use may sur- Lymphoma is a heterogeneous group of diseases rep- pass current guideline recommendations. The aim of the present resenting the fifth most common malignancy in the United study is to enlarge the growing body of evidence concerning 18F- FDG avidity of lymphoma to provide a basis for future guidelines. States, with an estimated 74,340 new cases predicted for Methods: The reports from 18F-FDG PET/CT studies performed 2008 (1). Subtypes of lymphoma differ in molecular char- in a single center for staging of 1,093 patients with newly diag- acteristics and biologic behavior. Based on clinical charac- nosed Hodgkin disease and non-Hodgkin lymphoma between teristics, this entity is divided into aggressive and indolent 2001 and 2008 were reviewed for the presence of 18F-FDG avid- types (2,3).
    [Show full text]
  • Successful Treatment of CD30+Lymphomatoid Papulosis
    ooggeenneessii iinn ss && rrcc aa MM CC uu tt ff aa Journal ofJournal of oo gg ll ee ee aa aa nn nn nn nn ee ee rr rr ss ss uu uu ii ii Watabe et al., J Carcinog Mutagen 2014, 5:3 ss ss oo oo JJ JJ ISSN: 2157-2518 CarCarcinogenesiscinogenesis & Mutagenesis DOI: 10.4172/2157-2518.1000174 Case Report Open Access Successful Treatment of CD30+Lymphomatoid Papulosis using a 308-nm Excimer Light Akiko Watabe, Taku Fujimura*, Sadanori Furudate and Setsuya Aiba Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan *Corresponding author: Taku Fujimura, Department of Dermatology, Tohoku University Graduate School of Medicine, Seiryo-machi 1-1, Aoba-ku, Sendai, 980-8574, Japan, Tel:+81 (22) 717-7271; Fax: +81 (22) 717-7361; E-mail: [email protected] Received date: Mar 11, 2014, Accepted date: May 03, 2014, Published date: May 07, 2014 Copyright: © 2013 Watabe A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Abstract We describe a 61-year-old Japanese patient with Lymphomatoid papulosis (LYP) successfully archived complete remission, using a 308-nm Excimer light. Interestingly, immunohistochemical staining revealed that CD30+ anaplastic tumor cells were surrounded by CD163+ macrophages and CCL18 producing cells, both of which were reported to correlate with the prognosis of CTCL. Our present study sheds light on the possible pathogenesis of LYP and the possibility of a 308-nm Excimer light phototherapy for LYP.
    [Show full text]
  • Lymphomatoid Papulosis Development in Acute Lymphoblastic Leukemia
    Case Report J Med Cases. 2021;12(8):306-309 Lymphomatoid Papulosis Development in Acute Lymphoblastic Leukemia Kazumi Ouraa, Tomonobu Satoa, d , Akihiro Iguchib, Naohisa Toriumic, Takeo Sarashinac Abstract LyP is a rare disease with an incidence of 1.2 - 1.9 per million [1] and accounts for 16.0-47.0% of pediatric cutaneous lym- Lymphomatoid papulosis (LyP) is a chronic, recurrent benign skin phoproliferative disorders [2]. It has been reported that LyP disease characterized by histological features of a CD 30-positive cu- often disappears spontaneously and has a benign course [3, taneous T-cell lymphoproliferative disorder. It is rare, with an annual, 4]. However, a relationship between LyP and certain hemato- worldwide incidence of 1.2 - 1.9 per million, and accounts for 16-47% logical malignancies has also been reported [5-7]. Herein, we of pediatric cutaneous lymphoproliferative disorders. It often occurs describe a case in which tumors appeared in the left scrotum on the extremities or the trunk and rarely affects the face or genitals. and under the left lip during maintenance therapy for pre- Its onset may be triggered by irradiation therapy, immunomodulating cursor B-cell acute lymphoblastic leukemia (BCP-ALL). We agents, infection or atopic dermatitis. It has a benign course but is as- needed to distinguish the tumor from extramedullary recur- sociated with certain hematological malignancies. Mycosis fungoides rence of ALL or de novo other cutaneous lymphoma; how- and primary cutaneous anaplastic large cell lymphoma are the most ever, the histological findings of a tumor biopsy resulted in a commonly associated hematological malignancies.
    [Show full text]
  • Co-Occurrence of Lymphomatoid Papulosis and Mycosis Fungoides in a Young Female: a Case Report Natalie Steinhoff, DO,* Brian Wanner,** Matthew H
    Co-Occurrence of Lymphomatoid Papulosis and Mycosis Fungoides in a Young Female: A Case Report Natalie Steinhoff, DO,* Brian Wanner,** Matthew H. Mahoney, MD*** *Dermatology Resident, PGY-3, Nova Southeastern University College of Osteopathic Medicine, Largo Medical Center, Largo, FL **Osteopathic Medical Student, 4th year, Des Moines University College of Osteopathic Medicine, Des Moines, IA ***Dermatologist and Clinical Faculty, Nova Southeastern University College of Osteopathic Medicine, Largo Medical Center, Largo, FL Disclosures: None Correspondence: Natalie Steinhoff, DO; NSUCOM/Largo Medical Center; 201 14th St. SW, Largo, FL 33770; [email protected] Abstract There have been reports of lymphomatoid papulosis (LyP) and mycosis fungoides (MF) presenting separately, simultaneously, and consecutively. LyP is a CD30+ lymphoproliferative disorder, and MF is the most common cutaneous T-cell lymphoma (CTCL). LyP most often presents with self-regressing, erythematous-to-brown papules or small nodules. Mycosis fungoides has a variety of clinical manifestations, but in early stages it commonly presents as an erythematous patch or plaque. Recognizing LyP is important due to its association with development of secondary malignancies, most commonly MF, Hodgkin’s disease, and anaplastic large-cell lymphoma (ALCL). We report a case of a 35-year-old woman with recurrent LyP lesions since childhood who went on to develop concurrent LyP and MF. We discuss the need to evaluate LyP patients for secondary lymphomas and provide a concise review of the literature focusing on clinical presentation, diagnosis, disease associations, and management. microabscesses (mycosis cells in the epidermis), Spontaneous self-regression of lesions is required Introduction 3 19 Lymphomatoid papulosis (LyP) is one of two and a band-like dermal infiltrate of lymphocytes.
    [Show full text]
  • Lymphomatoid Papulosis in Children a Retrospective Cohort Study of 35 Cases
    STUDY Lymphomatoid Papulosis in Children A Retrospective Cohort Study of 35 Cases Tamar Nijsten, MD; Clara Curiel-Lewandrowski, MD; Marshall E. Kadin, MD Background: Lymphomatoid papulosis (LyP) is a rare of follow-up was 9.0 years. All included patients were con- entity, considered to be part of the spectrum of the CD30+ firmed by histologic examination. cutaneous lymphoproliferative disorders. About 10% to 20% of the adult LyP patients will develop an associated Results: The age distribution was significantly differ- lymphoid malignancy. Only a few cases of LyP have been ent, with boys having an earlier onset of LyP (P=.03). described in children, and the risk of associated lym- Of the 35 LyP patients, 3 (9%) developed a malignant phoid malignancies in these patients is not known. lymphoma; all were diagnosed as having non-Hodgkin lymphoma. Compared with the general population, pa- Objectives: To study the association between child- tients with childhood-onset LyP have a significantly in- hood onset of LyP and other malignancies and to deter- creased risk of developing non-Hodgkin lymphoma (rela- mine the clinical characteristics in this subgroup of pa- tive risk, 226.2; 95% confidence interval, 73.4-697.0). tients. More than two thirds of the patients reported being atopic, which is significantly more than the expected preva- Design: Retrospective cohort study. lence of atopy (relative risk, 3.1; 95% confidence inter- val, 2.2-4.3). Setting: Referral center at a university hospital. Retro- spective registry for patients with LyP of childhood on- Conclusions: Lymphomatoid papulosis presents simi- set (Յ18 years).
    [Show full text]
  • Primary Cutaneous Lymphoma: ESMO Clinical Recommendations for Diagnosis, Treatment and Follow-Up R
    Annals of Oncology 19 (Supplement 2): ii72–ii76, 2008 clinical recommendations doi:10.1093/annonc/mdn095 Primary cutaneous lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up R. Dummer1 & M. Dreyling2 On behalf of the ESMO Guidelines Working Group* 1Department of Dermatology, University Hospital, Zu¨rich, Switzerland; 2Department of Medicine III, University Hospital Grosshadern, Munich, Germany introduction the quality of life due to their impact on skin appearance and annoying symptoms such as pruritus. In some cases they can Cutaneous lymphomas (CL) are the second most common already be disfiguring in early disease stages. In advanced stages, extranodal non-Hodgkin’s lymphomas. Their incidence is local skin problems are accompanied by systemic immune estimated at 1/100 000 yearly. Primary CL develop by definition suppression which results in an increased risk of infections and in the skin and remain confined to the skin for a long period of secondary malignancies. Some of the late-stage problems in time, while secondary CL reflect cutaneous spread from MF/SS patients might have been aggravated by earlier disseminated primary nodal or extranodal lymphomas. Primary therapeutic interventions, e.g. radiotherapy or phototherapy CL include a wide spectrum of clinically and histologically may contribute to mutations that increase the proliferative heterogeneous lymphoproliferative neoplasms: 75% of CL are and invasive capacity of the tumor cell populations. Cytotoxic cutaneous T-cell lymphomas (CTCL); 25% cutaneous B-cell drugs favor infectious complications. Most patients with lymphomas (CBCL); and a few percent other uncommon advanced disease may die due to secondary problems such as forms. CL and nodal or extracutaneous lymphomas with the infections.
    [Show full text]
  • Indolent Lymphoid Disorders Lazy Nothingness Or Incurable Lethality?
    Indolent Lymphoid Disorders Lazy nothingness or incurable lethality? Michael Tees, MD, MPH Hematology ~ Blood and Marrow Therapies Colorado Blood Cancer Institute Objectives Identify that indolent lymphomas should be considered indolent lymphoid disorders Understand the mortality implications of the indolent lymphoid disorders depending on age, treatment, and other prognostic factors Understand the long-term outcomes after hematopoietic cell transplantation Indolent Lymphoid Disorders Review What is indolent? Disease management and implications Survival and factors affecting mortality Indolent Lymphoid Disorders Review What is indolent? Disease management and implications Survival and factors affecting mortality Hematologic Malignancies Hematologic Disease US Incidence, 2015 estimate Total 162,020 Myeloid Acute Myeloid Leukemia 20,830 Chronic Myeloid Leukemia 6,660 Plasma Cell 26,850 Lymphoid Acute Lymphocytic Leukemia 6,250 Hodgkin Lymphoma 9,050 Non-Hodgkin Lymphoma 71,850 Chronic Lymphocytic Leukemia 14,620 Source: American Cancer Society, 2015 Hematopoiesis HSC Lymphoid Myeloid NK B T Indolent Lymphoid Disorders Review What is indolent? Disease management and implications Survival and factors affecting mortality Hematologic Malignancies Hematologic Disease US Incidence, 2015 estimate Total 162,020 Myeloid Acute Myeloid Leukemia 20,830 Chronic Myeloid Leukemia 6,660 Plasma Cell 26,850 Lymphoid Acute Lymphocytic Leukemia 6,250 Hodgkin Lymphoma 9,050 Non-Hodgkin Lymphoma 71,850 Chronic Lymphocytic Leukemia 14,620 Source: American Cancer
    [Show full text]
  • (WHO) Classification 2016
    Updated World Health Organization (WHO) Classification 2016 Mature B-cell neoplasms Chronic lymphocytic leukemia/small lymphocytic lymphoma Monoclonal B-cell lymphocytosis* B-cell prolymphocytic leukemia Splenic marginal zone lymphoma Hairy cell leukemia Splenic B-cell lymphoma/leukemia, unclassifiable Splenic diffuse red pulp small B-cell lymphoma Hairy cell leukemia-variant Lymphoplasmacytic lymphoma Waldenström macroglobulinemia Monoclonal gammopathy of undetermined significance (MGUS), IgM* μ heavy-chain disease γ heavy-chain disease α heavy-chain disease Monoclonal gammopathy of undetermined significance (MGUS), IgG/A* Plasma cell myeloma Solitary plasmacytoma of bone Extraosseous plasmacytoma Monoclonal immunoglobulin deposition diseases* Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) Nodal marginal zone lymphoma Pediatric nodal marginal zone lymphoma Follicular lymphoma In situ follicular neoplasia* Duodenal-type follicular lymphoma* Pediatric-type follicular lymphoma* Large B-cell lymphoma with IRF4 rearrangement* Primary cutaneous follicle center lymphoma Mantle cell lymphoma In situ mantle cell neoplasia* Diffuse large B-cell lymphoma (DLBCL), NOS Germinal center B-cell type* Activated B-cell type* T-cell/histiocyte-rich large B-cell lymphoma Primary DLBCL of the central nervous system (CNS) Primary cutaneous DLBCL, leg type EBV+ DLBCL, NOS* EBV+ mucocutaneous ulcer* DLBCL associated with chronic inflammation Lymphomatoid granulomatosis Primary mediastinal (thymic) large B-cell
    [Show full text]
  • Type B Follicular Lymphomatoid Papulosis
    Type B Follicular Lymphomatoid Papulosis Paru R. Chaudhari, BA; Patrick Emanuel, MD; Jacob Levitt, MD We report a 48-year-old woman who presented Case Report with waxing and waning papulovesicles of 4 years’ A 48-year-old obese woman with a history of geni- duration. Histologic examination revealed a fol- tal herpes presented to our clinic with intermittent liculotropic, small cell dominant, T cell lympho- nonpruritic papulovesicles on her torso of 4 years’ cytic infiltrate unaccompanied by follicular mucin duration. The papulovesicles would wax and wane deposition and with scattered intrafollicular and approximately every 3 months, and she associated perifollicular CD301 cells. A diagnosis of type B them with flulike symptoms of fatigue and myalgia. follicular lymphomatoid papulosis (LyP), rather She had seen 2 other dermatologists for her condi- than mycosis fungoides (MF), was made on the tion and both diagnosed folliculitis after multiple basis of her clinical presentation, which included skin biopsies. A retrospective review of these prior spontaneously resolving, waxing and waning pap- biopsies revealed a relatively dense folliculotropic ules that healed with scarring. Type B follicular infiltrate. She took several medications throughout LyP is a rare form of LyP. the last 4 years; however, the onset of her skin con- Cutis. 2010;85:307-311. dition had no consistent temporal association with medication intake. On physical examination, she CUTISwas noted to have red papulovesicles on the trunk nitially described by Macaulay1 in 1968, lympho- and arms, some with excoriation and ulceration and matoid papulosis (LyP) is a disorder characterized some with scale (Figure 1). No lymphadenopathy or I by remitting and recurring papules and nod- hepatosplenomegaly was present.
    [Show full text]